invIOs is advancing a focused PIPELINE OF PROGRAMS encompassing small-molecule and cell-therapy approaches.
Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into CLINICAL TRIALS.
INV501 is a high-potential orally available immune-activating small molecule in pre-clinical development.
INV501 activates tumor-specific immune cells by binding to a novel, undisclosed target currently under investigation.
By screening for compounds with high potential to enhance T-cell activity in an antigen-specific manner, we identified a distinct substance class and have declared a lead candidate with profound capacity for tumor-specific immune activation.
In pre-clinical evaluation, INV501 has generated strong data on in vivo inhibition of tumor growth in multiple solid tumor indications.
The first program from our EPiC cell-therapy platform, APN401 is currently in Phase 1 clinical trials in patients with various solid tumors.
APN401 leverages our proprietary rapid cell processing technology to create an individualized treatment based on the patient’s own white blood cells (peripheral blood mononuclear cells – PBMCs).
Our novel approach uses siRNA to transiently silence the master immune checkpoint Cbl-b, resulting in highly activated tumor-reactive PBMCs. Multiple treatment cycles each using freshly isolated PBMCs can increase the memory effect, leading to a higher immune cell count and counteracting the treatment-induced resistance of cancer cells.
In 2022, we completed a Phase 1 trial of APN401 demonstrating the feasibility of integrating our EPiC cell-processing platform technology into daily clinical routine. We presented promising patient data from the trial at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
A previous first-in-human trial showed that single and multiple dose infusions of APN401 were well tolerated, with no serious side effects.
Our second EPiC program, INV441 is being developed against glioblastoma multiforme (GBM), one of the highest areas of unmet medical need in oncology today.
INV441 leverages our rapid cell-processing technology to silence Cbl-b in tumor infiltrating lymphocytes (TILs) using siRNA.
The modified TILs are resistant to the immune-suppressive tumor microenvironment (TME), resulting in re-activation of anti-tumor immunity and leading to high potential for tumor cell killing.
INV441 is currently completing pre-clinical development, with clinical trials planned starting in 2024.